Aetna CFO says spent $30 mln on Sovaldi in Q1, as expected
April 24, 2014 at 09:30 AM EDT
April 24 (Reuters) - Aetna Inc. spent about $30 million during the first quarter on Sovaldi, the pricey new hepatitis C treatment from Gilead Sciences Inc., Chief Financial Officer Shawn Guertin said on Thursday during a conference call with investors.